Pages that link to "Q27851705"
Jump to navigation
Jump to search
The following pages link to Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial (Q27851705):
Displaying 50 items.
- Relevance of Pathological Complete Response after Neoadjuvant Therapy for Breast Cancer (Q26740393) (← links)
- Neoadjuvant nab-paclitaxel in the treatment of breast cancer (Q26748822) (← links)
- Hormone Receptor/Human Epidermal Growth Factor Receptor 2-positive breast cancer: Where we are now and where we are going (Q26750740) (← links)
- Mechanisms Behind the Resistance to Trastuzumab in HER2-Amplified Breast Cancer and Strategies to Overcome It (Q26752780) (← links)
- Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2 breast cancer (Q26772969) (← links)
- National consensus in China on diagnosis and treatment of patients with advanced breast cancer (Q26775621) (← links)
- Targeted Therapies in HER2-Positive Breast Cancer - a Systematic Review (Q26777733) (← links)
- Biological markers of invasive breast cancer (Q26781177) (← links)
- Dual HER2 blockade in the neoadjuvant and adjuvant treatment of HER2-positive breast cancer (Q26785612) (← links)
- Potential of overcoming resistance to HER2-targeted therapies through the PI3K/Akt/mTOR pathway (Q26799382) (← links)
- Potential of afatinib in the treatment of patients with HER2-positive breast cancer (Q26999050) (← links)
- Neoadjuvant therapy of early stage human epidermal growth factor receptor 2 positive breast cancer: latest evidence and clinical implications (Q27001729) (← links)
- Serum biomarkers for the detection of cardiac toxicity after chemotherapy and radiation therapy in breast cancer patients (Q27007849) (← links)
- Profiling and targeting HER2-positive breast cancer using trastuzumab emtansine (Q27015048) (← links)
- Quantification of HER family receptors in breast cancer (Q27015506) (← links)
- Human epidermal growth factor receptor family-targeted therapies in the treatment of HER2-overexpressing breast cancer (Q27025863) (← links)
- AGO Recommendations for the Diagnosis and Treatment of Patients with Advanced and Metastatic Breast Cancer: Update 2015. (Q27343148) (← links)
- CIViC database (Q27612411) (← links)
- Neoadjuvant therapy in the treatment of breast cancer (Q27694514) (← links)
- ERBB2 Amplification (Q27908387) (← links)
- Restoring Lost Anti-HER-2 Th1 Immunity in Breast Cancer: A Crucial Role for Th1 Cytokines in Therapy and Prevention (Q28067145) (← links)
- Molecular Mechanisms and Translational Therapies for Human Epidermal Receptor 2 Positive Breast Cancer (Q28072513) (← links)
- Resistance to therapy in estrogen receptor positive and human epidermal growth factor 2 positive breast cancers: progress with latest therapeutic strategies (Q28072897) (← links)
- Twenty years of anti-HER2 therapy-associated cardiotoxicity (Q28079391) (← links)
- Treatment of early-stage HER2 breast cancer-an evolving field (Q28081124) (← links)
- PI3K mutations in breast cancer: prognostic and therapeutic implications (Q28081992) (← links)
- From bench to bedside: What do we know about hormone receptor-positive and human epidermal growth factor receptor 2-positive breast cancer? (Q28084982) (← links)
- Systemic targeted therapy for her2-positive early female breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline (Q28260063) (← links)
- Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA) (Q28291395) (← links)
- Differential inhibition of ex-vivo tumor kinase activity by vemurafenib in BRAF(V600E) and BRAF wild-type metastatic malignant melanoma (Q28536351) (← links)
- Translating neoadjuvant therapy into survival benefits: one size does not fit all. (Q30251738) (← links)
- Sustained zero-order release of intact ultra-stable drug-loaded liposomes from an implantable nanochannel delivery system (Q30574926) (← links)
- Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial (Q30758991) (← links)
- Strategies to overcome trastuzumab resistance in HER2-overexpressing breast cancers: focus on new data from clinical trials. (Q30857631) (← links)
- Dual HER2 blockade: preclinical and clinical data (Q30941327) (← links)
- Non-anthracycline-containing docetaxel and cyclophosphamide regimen is associated with sustained worse outcome compared with docetaxel, anthracycline and cyclophosphamide in neoadjuvant treatment of triple negative and HER2-positive breast cancer pa (Q31160308) (← links)
- Paclitaxel, carboplatin, and trastuzumab in a neo-adjuvant regimen for HER2-positive breast cancer (Q33407805) (← links)
- Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial (Q33415041) (← links)
- Retrospective study of the efficacy and safety of neoadjuvant docetaxel, carboplatin, trastuzumab/pertuzumab (TCH-P) in nonmetastatic HER2-positive breast cancer. (Q33433275) (← links)
- Pathological complete response as a surrogate for relapse-free survival in patients with triple negative breast cancer after neoadjuvant chemotherapy (Q33566963) (← links)
- Challenges in the Treatment of Triple Negative and HER2-Overexpressing Breast Cancer (Q33576608) (← links)
- ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics (Q33601653) (← links)
- Optimal approach in early breast cancer: Adjuvant and neoadjuvant treatment (Q33698446) (← links)
- Differential expression of VEGFR2 protein in HER2 positive primary human breast cancer: potential relevance to anti-angiogenic therapies (Q33709284) (← links)
- Immune Signatures Following Single Dose Trastuzumab Predict Pathologic Response to PreoperativeTrastuzumab and Chemotherapy in HER2-Positive Early Breast Cancer (Q33712476) (← links)
- Impact of hormone receptor status on patterns of recurrence and clinical outcomes among patients with human epidermal growth factor-2-positive breast cancer in the National Comprehensive Cancer Network: a prospective cohort study (Q33739253) (← links)
- Unique molecular signatures as a hallmark of patients with metastatic breast cancer: implications for current treatment paradigms (Q33756991) (← links)
- An open-label safety study of lapatinib plus trastuzumab plus paclitaxel in first-line HER2-positive metastatic breast cancer. (Q33777427) (← links)
- Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. (Q33827808) (← links)
- ERRF sensitizes ERBB2-positive breast cancer cells to lapatinib treatment likely by attenuating MCL1 and ERBB2 expression (Q33829405) (← links)